Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor

We measured serum osteocalcin levels in prepubertal children with human immunodeficiency virus (HIV) infection receiving highly active antiretroviral therapy including a protease inhibitor and uninfected control children. Osteocalcin values were significantly elevated in the HIV-infected patients. T...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 2001-09, Vol.139 (3), p.447-451
Main Authors: Tan, Belen M., Nelson, Robert P., James-Yarish, Michelle, Emmanuel, Patricia J., Schurman, Scott J.
Format: Article
Language:English
Subjects:
Antiretroviral Therapy, Highly Active
Bone and Bones - metabolism
Carboxyterminal telopeptide of
Case-Control Studies
Child
Child, Preschool
Cross-Sectional Studies
Female
HAART
Highly active anti-retroviral therapy
HIV
HIV Infections - drug therapy
HIV Infections - metabolism
HIV Protease Inhibitors - therapeutic use
Human immunodeficiency virus
Humans
ICTP
Male
Osteocalcin - blood
Protease inhibitor
type I collagen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We measured serum osteocalcin levels in prepubertal children with human immunodeficiency virus (HIV) infection receiving highly active antiretroviral therapy including a protease inhibitor and uninfected control children. Osteocalcin values were significantly elevated in the HIV-infected patients. Though osteocalcin serves as an index of bone formation, it likely functions as a negative regulator of bone formation. Further study is necessary to determine whether protease inhibitors normalize bone physiology or decrease bone formation and reduce bone mineral density in children receiving these therapies. (J Pediatr 2001;139:447-51)
ISSN:0022-3476
1097-6833
DOI:10.1067/mpd.2001.117005